Prelude Therapeutics Incorporated growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +138.9%
EBITDA: +43.9%
EBIT: +39.9%
EPS: +37.3%
Free cash flow: +58.6%
Operating cash flow: +58.5%

Forward estimates

Revenue: +237.9%
EBITDA: +144.5%
EPS: +93.9%

Three-year CAGR

Revenue: +73.4%
EBITDA: +22.0%
EBIT: +25.2%
Net income: +21.8%
EPS: +23.2%
Free cash flow: +45.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.